NCT04932434View on ClinicalTrials.gov

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 15, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Parkinson DiseaseDepressionAnxiety
Interventions
DRUG

Psilocybin therapy

"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Joshua Woolley, MD, PhD

OTHER

NCT04932434 - Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease | Biotech Hunter | Biotech Hunter